Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

US FDA is ‘willing to look at anything’ but sponsors need to demonstrate an effect on pain as drug development challenges remain. Accompanying chart describes 32 drugs in Phase II and Phase III clinical trials and one with a pending biologics license application.